Dr. Joe Zhou ,President and Chief Scientist, Genor Biopharma Co. Ltd.

发布时间:2020-07-08
Dr. Joe Zhou ,President and Chief Scientist, Genor Biopharma Co. Ltd.

微信截图_20200630105405

Dr. Joe Zhou ,President and Chief Scientist, Genor Biopharma Co. Ltd.

Topic: Global mAb Industry:Key Consideration for mAb and Biological Therapeutics


Speaker Bio

Dr. Joe Zhou,President and Chief Scientist of Genor BioPharma, Visiting Professor of Peking University. Previously, Dr. Zhou was Scientific Director at Amgen, Thous and Oaks, USA. His over 20-years experience of process development, multiple project management capacity in cGMP and non-GMP reproducible purification/production of protein/antibody therapeutics from FIH to CPD with depth knowledge of CHO clone selection, cell culture optimization, real time analytical assays, formulation and product specification for drug substances and drug products made Dr. Zhou many times as Project Process Team Leader/Project Team Leader/Cross Functional Core Investigation Teams Leaders at Amgen in the past.

Dr.Zhou has proven bio-industrial leadership in scientific innovation and technology evaluation, and is well known for implementation of membrane chromatography in mAb large-scale processing. Dr. Zhou has excellent reputation and an extended external network in the Process Development and or Process science peer community due to his extensive speaking and publication record including research articles, patents and book chapters in the Process Development and Process science field. Dr.Zhou has proven records for design space for process robustness and viral clearance in mAb production. Dr. Zhou was awarded as 2007 Amgen "Excellence in Science and Engineering” for his Major achievement and leadership on photo-oxidation on monoclonal antibody yellowing, and selected by Amgen as a visiting professor teaching the GMP Masters Degree Program at PKU, Peoples Republic of CHINA since 2007.


Presentation Summary

1. Changes in the global situation of antibodies and biological drugs;

2. The trend of cancer from an acute disease lacking medical care and medicine to a chronic disease;

3. The maturity of antibody drug process technology accelerates the decline of drug prices;

4. Future market demand: opportunities and challenges;

5. Conclusion.


0
-1